Ajoene, an experimental anti-leukemic drug: mechanism of cell death

被引:0
|
作者
VM Dirsch
DSM Antlsperger
H Hentze
AM Vollmar
机构
[1] Center of Drug Research,Department of Pharmacy
[2] University of Munich,undefined
[3] Biochemical Pharmacology,undefined
[4] University of Konstanz,undefined
[5] Institute of Molecular and Cell Biology (IMBC),undefined
来源
Leukemia | 2002年 / 16卷
关键词
apoptosis; organosulfur compound; caspases; mitochondria; HL-60;
D O I
暂无
中图分类号
学科分类号
摘要
The organosulfur compound ajoene, a constitutent of garlic, has been shown to induce apoptosis in a leukemic cell line as well as in blood cells of a leukemic patient. The mechanisms of action of ajoene, however, are unknown. The present study aims to characterize the molecular events leading to ajoene-triggered apoptosis. We show here that ajoene (20 μM) leads to a time-dependent activation of caspase-3-like activity as well as to the proteolytic processing of procaspase-3 and -8. Activation of caspases was necessary for ajoene-induced apoptosis since the broad-range caspase inhibitor zVAD-fmk completely abrogated ajoene-mediated DNA fragmentation. Although the initiator caspase-8 was activated, the CD95 death receptor was not involved in death signaling since the HL-60 clone used was shown to express a functionally inactive CD95 receptor. Furthermore, ajoene induced the release of cytochrome c, which was not inhibited by zVAD-fmk indicating that cytochrome c release precedes caspase activation. Ajoene also led to a dissipation of the mitochondrial transmembrane potential. Overexpression of Bcl-xL clearly diminished ajoene-induced caspase activation as well as apoptosis. These results indicate that apoptosis in leukemia cells triggered by ajoene is based on the activation of a mitochondria-dependent caspase cascade which includes also the activation of the initiator caspase-8.
引用
收藏
页码:74 / 83
页数:9
相关论文
共 50 条
  • [1] Ajoene, an experimental anti-leukemic drug: mechanism of cell death
    Dirsch, VM
    Antlsperger, DSM
    Hentze, H
    Vollmar, AM
    LEUKEMIA, 2002, 16 (01) : 74 - 83
  • [2] THE ANTI-LEUKEMIC ACTION OF COMBINATIONS OF CERTAIN KNOWN ANTI-LEUKEMIC AGENTS
    SKIPPER, HE
    CHAPMAN, JB
    BELL, M
    CANCER RESEARCH, 1951, 11 (02) : 109 - 112
  • [3] IMP DEHYDROGENASE - INHIBITION BY THE ANTI-LEUKEMIC DRUG, TIAZOFURIN
    YAMADA, Y
    NATSUMEDA, Y
    YAMAJI, Y
    JAYARAM, HN
    TRICOT, GJ
    HOFFMAN, R
    WEBER, G
    LEUKEMIA RESEARCH, 1989, 13 (02) : 179 - 184
  • [4] MECHANISM OF ACTION OF ANTI-LEUKEMIC AGENTS - INHIBITION OF DNA-POLYMERASES
    TANAKA, M
    YOSHIDA, S
    ACTA HAEMATOLOGICA JAPONICA, 1980, 43 (06): : 996 - 1003
  • [5] HEXAPHOSPHAMIDE - A NEW ANTI-LEUKEMIC AGENT
    KARPAVICHUS, KI
    KHOMCHENOVSKY, EI
    PUODZHYANAITE, BA
    KHIMIKO-FARMATSEVTICHESKII ZHURNAL, 1980, 14 (06): : 119 - 122
  • [6] Anti-leukemic effects of PPARγ ligands
    Ryu, Somi
    Kim, Dae Seong
    Lee, Myoung Woo
    Lee, Ji Won
    Sung, Ki Woong
    Koo, Hong Hoe
    Yoo, Keon Hee
    CANCER LETTERS, 2018, 418 : 10 - 19
  • [7] Promising anti-leukemic activity of atorvastatin
    Zolnierczyk, Jolanta D.
    Borowiak, Arleta
    Hikisz, Pawel
    Cebula-Obrzut, Barbara
    Blonski, Jerzy Z.
    Smolewski, Piotr
    Robak, Tadeusz
    Kilianska, Zofia M.
    ONCOLOGY REPORTS, 2013, 29 (05) : 2065 - 2071
  • [8] TERATOGENIC EFFECTS OF ANTI-LEUKEMIC CHEMOTHERAPY
    SCHAFER, AI
    ARCHIVES OF INTERNAL MEDICINE, 1981, 141 (04) : 514 - 515
  • [9] THERAPEUTIC POTENTIATION OF ANTI-LEUKEMIC DRUGS
    SCHABEL, FM
    LASTER, WR
    TRADER, MW
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1968, 9 (MAR): : 62 - &
  • [10] The Anti-Leukemic Activity of Natural Compounds
    Cotoraci, Coralia
    Ciceu, Alina
    Sasu, Alciona
    Miutescu, Eftimie
    Hermenean, Anca
    MOLECULES, 2021, 26 (09):